TW268951B - - Google Patents

Info

Publication number
TW268951B
TW268951B TW081110118A TW81110118A TW268951B TW 268951 B TW268951 B TW 268951B TW 081110118 A TW081110118 A TW 081110118A TW 81110118 A TW81110118 A TW 81110118A TW 268951 B TW268951 B TW 268951B
Authority
TW
Taiwan
Prior art keywords
compound
formula
disclosed
pharmaceutically acceptable
effective amount
Prior art date
Application number
TW081110118A
Other languages
English (en)
Chinese (zh)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of TW268951B publication Critical patent/TW268951B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW081110118A 1991-12-18 1992-12-17 TW268951B (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81064291A 1991-12-18 1991-12-18

Publications (1)

Publication Number Publication Date
TW268951B true TW268951B (enExample) 1996-01-21

Family

ID=25204324

Family Applications (1)

Application Number Title Priority Date Filing Date
TW081110118A TW268951B (enExample) 1991-12-18 1992-12-17

Country Status (17)

Country Link
EP (1) EP0618905B1 (enExample)
JP (1) JP2540015B2 (enExample)
KR (2) KR940703814A (enExample)
AT (1) ATE128708T1 (enExample)
AU (1) AU662588B2 (enExample)
CA (1) CA2125964C (enExample)
DE (1) DE69205287T2 (enExample)
DK (1) DK0618905T3 (enExample)
ES (1) ES2078118T3 (enExample)
GR (1) GR3018474T3 (enExample)
HK (1) HK185696A (enExample)
IL (1) IL104126A (enExample)
MY (1) MY108119A (enExample)
NZ (1) NZ246295A (enExample)
TW (1) TW268951B (enExample)
WO (1) WO1993012093A1 (enExample)
ZA (1) ZA929786B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010065033A (ja) * 2008-09-04 2010-03-25 Gracel Display Inc 新規の有機電界発光化合物およびこれを使用する有機電界発光素子
JP2011132163A (ja) * 2009-12-24 2011-07-07 Shin-Etsu Chemical Co Ltd 反応性シリル基を有するトリアリールアミン誘導体及び無機材料並びに色素増感型光電変換素子

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681956A (en) * 1990-12-28 1997-10-28 Neurogen Corporation 4-aryl substituted piperazinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype specific ligands
US5633376A (en) * 1990-12-28 1997-05-27 Neurogen Corporation Certain aminomethyl phenylimidazole derivatives; and 4-aryl substituted piperazinyl and piperidinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype ligands
US5646281A (en) * 1990-12-28 1997-07-08 Neurogen Corporation Certain 4-piperidino- and piperazinomethyl-2-phenyl imidazole derivatives; dopamine receptor subtype specific ligands
US5646280A (en) * 1990-12-28 1997-07-08 Neurogen Corporation Substituted 4-(alkyl, dialkyl) or cycloaklyl)aminomethyl 2-phenylimidazoes: dopamine receptor subtype specific ligands
CA2101311A1 (en) * 1992-07-31 1994-02-01 Neelakantan Balasubramanian Adenosine re-uptake inhibiting derivatives of diphenyl oxazoles, thiazoles and imidazoles
DE4311968A1 (de) * 1993-04-10 1994-10-20 Hoechst Ag Smektische Flüssigkristallmischung
CA2222652A1 (en) * 1995-06-07 1996-12-19 Gliatech, Inc. 1h-4(5)-substituted imidazole derivatives
US6072057A (en) * 1996-06-06 2000-06-06 Gliatech Inc. 1H-4(5)-cyclo-substituted imidazole derivatives as histamine H3 receptor agents
US6407132B1 (en) 1997-07-25 2002-06-18 James Black Foundation Limited Substituted imidazole derivatives and their use as histamine H3 receptor ligands
US6133291A (en) * 1998-10-16 2000-10-17 Schering Corporation N-(imidazolylalkyl)substituted cyclic amines as histamine-H3 agonists or antagonists
JP2002534511A (ja) 1999-01-18 2002-10-15 ノボ ノルディスク アクティーゼルスカブ 置換型イミダゾール、それらの調製及び使用
US6211182B1 (en) 1999-03-08 2001-04-03 Schering Corporation Imidazole compounds substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms
TW575561B (en) * 1999-03-25 2004-02-11 Hoffmann La Roche 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives
US6908926B1 (en) 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
US6437147B1 (en) 2000-03-17 2002-08-20 Novo Nordisk Imidazole compounds
US6610721B2 (en) 2000-03-17 2003-08-26 Novo Nordisk A/S Imidazo heterocyclic compounds
MY120281A (en) 2000-09-20 2005-09-30 Schering Corp Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
EP1318996B1 (en) 2000-09-20 2004-12-01 Schering Corporation Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
ATE411983T1 (de) 2000-09-20 2008-11-15 Schering Corp Substituierte imidazole als histamine h1 und h3 agonisten oder antagonisten
CA2421826C (en) 2000-09-20 2009-10-27 Schering Corporation Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
FR2827863A1 (fr) * 2001-07-27 2003-01-31 Sanofi Synthelabo Derives d'aminoalkylimidazole, leur preparation et leur utilisation en therapeutique
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
WO2010133544A1 (en) * 2009-05-22 2010-11-25 Evotec Ag Piperazine and aminopyrrolidine compounds as histamine h3 receptor antagonists
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2579596B1 (fr) * 1985-03-26 1987-11-20 Inst Nat Sante Rech Med (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique
FR2586562B1 (fr) * 1985-09-02 1989-03-10 Inst Nat Sante Rech Med Composition pharmaceutique contenant de l'a-methylhistamine
US4829065A (en) * 1987-04-24 1989-05-09 Syntex Pharmaceuticals, Ltd. Substituted imidazolyl-alkyl-piperazine and -diazepine derivatives
FR2630328B1 (fr) * 1988-04-22 1990-08-24 Inst Nat Sante Rech Med Derive de l'histamine, sa preparation et son application en therapeutique
FR2661909B1 (fr) * 1990-05-09 1997-08-14 Inst Nat Sante Rech Med Nouveaux composes agonistes du recepteur h3 de l'histamine a usage therapeutique, compositions pharmaceutiques agissant comme agonistes dudit recepteur et procede de preparation.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010065033A (ja) * 2008-09-04 2010-03-25 Gracel Display Inc 新規の有機電界発光化合物およびこれを使用する有機電界発光素子
JP2011132163A (ja) * 2009-12-24 2011-07-07 Shin-Etsu Chemical Co Ltd 反応性シリル基を有するトリアリールアミン誘導体及び無機材料並びに色素増感型光電変換素子

Also Published As

Publication number Publication date
WO1993012093A1 (en) 1993-06-24
AU3247793A (en) 1993-07-19
EP0618905A1 (en) 1994-10-12
HK185696A (en) 1996-10-11
KR0136207B1 (en) 1998-04-25
ZA929786B (en) 1993-06-18
CA2125964C (en) 2001-06-19
JPH06511251A (ja) 1994-12-15
DE69205287T2 (de) 1996-03-14
GR3018474T3 (en) 1996-03-31
AU662588B2 (en) 1995-09-07
MY108119A (en) 1996-08-15
ATE128708T1 (de) 1995-10-15
IL104126A0 (en) 1993-05-13
CA2125964A1 (en) 1993-06-24
DE69205287D1 (de) 1995-11-09
DK0618905T3 (da) 1995-12-04
EP0618905B1 (en) 1995-10-04
KR940703814A (ko) 1994-12-12
JP2540015B2 (ja) 1996-10-02
ES2078118T3 (es) 1995-12-01
NZ246295A (en) 1996-06-25
IL104126A (en) 1999-05-09

Similar Documents

Publication Publication Date Title
TW268951B (enExample)
TW263503B (enExample)
TW268950B (enExample)
DE3177092D1 (en) Medicinal composition for treatment of allergic diseases
GR3020497T3 (en) New chroman and thiochroman derivatives
NO962538L (no) 6-(2-imidazolinylamino)kinoksalin-forbindelser anvendbare som -2-adrenoceptor-agonister
WO1999024421A8 (en) Imidazoylalkyl substituted with a five, six or seven membered heterocyclic ring containing one nitrogen atom
FI92320B (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten bisfenyylialkyylipiperatsiinijohdannaisten valmistamiseksi
NO961180L (no) Transdermal anordning inneholdende (E)-2-(p-fluorfenetyl)-3-fluorallylamin for behandling av Alzheimers sykdom
NO930083L (no) Sammensetning for behandling av alzheimers sykdom og fremgangsmaate for fremstilling av samme